3
Announcements
Trials
Browse
Landscape
Phase
Phase 4
2
Phase 3
2
Phase 1
1
Status
Terminated
1
Recruiting
1
Sponsor Class
INDUSTRY
2
Study Type
Interventional
2
Sponsor
Cancer Type
Classical hematology
11
Gastrointestinal
2
Other hematologic neoplasm
1
CNS
1
Conditions
Colorectal Neoplasms
439
Stomach Neoplasms
248
Carcinoma, Hepatocellular
246
Rectal Neoplasms
211
Colonic Neoplasms
204
Pancreatic Neoplasms
172
Esophageal Neoplasms
113
Neoplasm Metastasis
75
Liver Neoplasms
71
Esophageal Squamous Cell Carcinoma
64
Neoplasms
63
Gastrointestinal Stromal Tumors
36
Cholangiocarcinoma
36
Gastrointestinal Neoplasms
31
Parkinson Disease 4, Autosomal Dominant Lewy Body
25
Gallbladder Neoplasms
25
Adenocarcinoma Of Esophagus
24
Biliary Tract Neoplasms
23
Anus Neoplasms
22
Adenocarcinoma
21
Recurrence
19
Bile Duct Neoplasms
19
Breast Neoplasms
18
Digestive System Neoplasms
17
Lung Neoplasms
13
Prostatic Neoplasms
12
Uterine Cervical Neoplasms
11
Carcinoma
11
Digestive System Diseases
10
Peritoneal Neoplasms
9
Interventions
isoquercitrin
1
abelacimab
1
MAA868
1
Dalteparin
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
Phase 3
×
Pulmonary Embolism
×
Gastrointestinal
×
Clear all
NCT05171075
2026-04-17
MAGNOLIA
Anthos Therapeutics, Inc.
Phase 3
Terminated
417 enrolled
NCT06861088
2026-02-02
CATIQ P3
Quercis Pharma AG
Phase 3
Recruiting
480 enrolled